Ideaya Biosciences Inc

NASDAQ:IDYA

22.10

+0.18 (+0.82%)

: $22.10 0.00 (0.00%)

Market Cap (Intraday)	1.95B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$3.81 Million
Adjusted EPS	-$0.79

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Ideaya Biosciences Inc Stock, NASDAQ:IDYA

5000 Shoreline Court, Suite 300, South San Francisco, California 94080

United States of America

Phone: +1.650.443.6209

Number of Employees: 131

http://www.ideayabio.com

Description

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.